-+ 0.00%
-+ 0.00%
-+ 0.00%

Palvella reports Phase 3 SELVA, Phase 2 TOIVA QTORIN rapamycin results slated for ISSVA 2026

PUBT·04/20/2026 11:30:48
Listen to the news
Palvella reports Phase 3 SELVA, Phase 2 TOIVA QTORIN rapamycin results slated for ISSVA 2026
  • Palvella Therapeutics flagged late-breaking clinical results for QTORIN rapamycin gel from Phase 3 SELVA and Phase 2 TOIVA studies for presentation at ISSVA World Congress 2026.
  • Data will be presented May 20, 2026 at 4:30 p.m. ET in Philadelphia.
  • Studies showed statistically significant, clinically meaningful improvement in microcystic lymphatic malformations.
  • Results also indicated clinically meaningful improvement in cutaneous venous malformations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200730PRIMZONEFULLFEED9692780) on April 20, 2026, and is solely responsible for the information contained therein.